Results 81 to 90 of about 18,044 (238)

Biosimilars [PDF]

Zeitschrift für Rheumatologie, 2015
G.-R. Burmester, U. Müller-Ladner
  +8 more sources

Improving the managed introduction of new medicines : sharing experiences to aid authorities across Europe [PDF]

, 2015
The 3-day course on the managed introduction of new drugs was organised by the Piperska group together with the Agency for Health Technology Assessment and Tariff System (AOTMiT) and WHO Europe to share experiences and case histories among health ...
Bak Pedersen, Hanne, Fürst, Jurij, Godman, Brian, Gulbinovič, Jolanta, Mack, Asbjørn, Malmström, Rickard E, Matusewicz, Wojciech, Selke, Gisbert, Timoney, Angela, Warmińska, Ewa   +9 more
core   +1 more source

Recent Advances (2023–2025) of Capillary Electrophoresis‐Mass Spectrometry (CE‐MS) for Top‐Down Proteomics

Mass Spectrometry Reviews, EarlyView.
ABSTRACT Top‐down proteomics (TDP) characterizes proteoforms in cells, tissues, and biofluids, in discovery mode and on a global scale, requiring analytical tools with high peak capacity for proteoform separation and high sensitivity for proteoform detection, given the extremely high proteoform complexity and wide proteoform concentration dynamic range.
Guijie Zhu, David A. Alvarez Rodriguez, Noah Gould, Alexander R. Ivanov, Kevin Jooß, Liangliang Sun   +5 more
wiley   +1 more source

Advancing pharmacometrics in Africa—Transition from capacity development toward job creation

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 407-419, March 2025.
Abstract Trained pharmacometricians remain scarce in Africa due to limited training opportunities, lack of a pharmaceutical product development ecosystem, and emigration to high‐income countries. The Applied Pharmacometrics Training (APT) fellowship program was established to address these gaps and specifically foster job creation for talent retention.
Goonaseelan (Colin) Pillai, Samer Mouksassi, Innocent G. Asiimwe, Craig R. Rayner, Steven Kern, Phumla Sinxadi, Paolo Denti, Eric Decloedt, Catriona Waitt, Bernhards R. Ogutu, Rik de Greef   +10 more
wiley   +1 more source

Evaluation of rheumatologists’ knowledge of biosimilars

Advances in Rheumatology
Introduction Biosimilars reduce the cost of biologic therapy without compromising safety and effectiveness. In this study we evaluated Brazilian rheumatologists’ knowledge and perceptions of biosimilars.
Thayane Furtado Rolim Lima, Lia Poti Gomes Cordeiro, Kirla Wagner Poti Gomes, Carlos Ewerton Maia Rodrigues   +3 more
doaj   +1 more source

Biosimilar infliximab introduction into the gastro-enterology care pathway in a large acute Irish teaching hospital: a story behind the evidence [PDF]

, 2018
Background and aim: Biosimilar medicines are not considered exact replicas of originator biological medicines. As a result, prescribers can be hesitant to introduce such medicines into the clinical setting until evidence surfaces confirming their safety ...
Byrne, Stephen, Carrol, Donal, Courtney, Garry, Mulcahy, Mark, O'Brien, Gary L., Walshe, Valerie   +5 more
core   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. [PDF]

, 2019
BACKGROUND AND AIMS:Treatment pathways for ulcerative colitis (UC) and Crohn's disease (CD) are shifting to a more individualized, risk-stratified approach.
Cao, Charlie, Dulai, Parambir S, Lasch, Karen, Osterman, Mark T, Riaz, Faisal, Sandborn, William J   +5 more
core  

Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays [PDF]

, 2017
Background: The commercialization of CT-P13, an infliximab (IFX) biosimilar, has the potential to decrease health-related costs and enhance access to biological therapies.
Cláudia Camila Dias, Fernando Magro, Gonczi L, Helena Tavares de Sousa, Isadora Rosa, Joana Afonso, João Carvalho   +6 more
core   +1 more source

A Case for Anti‐IgE Vaccination

Allergy, EarlyView.
ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff, Zahra Gharailoo, Monique Vogel, Martin F. Bachmann   +3 more
wiley   +1 more source